Gene-modified, donor cell therapy – Page 4

Targeting pancreatic cancer with Allogeneic Off-the-Shelf PSCA-CAR NK cells

Post author:
Post published:December 1, 2025
Post category:

Translational Candidate PSCA-CAR_sIL15 NK cells derived from CD34(+) umbilical cord blood hematopoietic stem cells Area of Impact patients with metastatic pancreatic cancer or other cancers that also highly express PSCA…

Combating Ovarian Cancer with Stem Cell-Engineered Off-The-Shelf CAR-NKT Cell Therapy

Post author:
Post published:December 1, 2025
Post category:

Translational Candidate stem cell-based off-the-shelf CAR-NKT cells Area of Impact ovarian cancer (OC) Mechanism of Action The proposed cell therapy candidate, AlloMCAR-NKT cells, can directly kill OC tumor cells through…

Hypoimmunogenic iPSC-derived TCR-NK cells for oncology

Post author:
Post published:December 1, 2025
Post category:

Translational Candidate iPSC-derived NY-ESO-1 TCR/IL-15 NK cells Area of Impact NK drug product homogeneity and engraftment/response durability will be improved by this hypoimmunogenic iPSC-TCR-NK therapy in cancer patients Mechanism of…

Targeting multiple myeloma with BCMA-CAR NK cells expressing a GPRC5D-NKG2D bispecific antibody

Post author:
Post published:December 1, 2025
Post category:

Translational Candidate s15.BsAb.BCMA-CAR NK cells derived from CD34(+) umbilical cord blood hematopoietic stem cells Area of Impact patients with multiple myeloma Mechanism of Action s15.BsAb.BCMA-CAR NK cells are umbilical cord…

Specific Targeting Hypoxia Metastatic Breast Tumor with Allogeneic Off-the-Shelf Anti-EGFR CAR NK Cells Expressing an ODD domain of HIF-1α

Post author:
Post published:December 1, 2025
Post category:

Translational Candidate EGFR-CAR_sIL15 NK cells derived from CD34(+) umbilical cord blood hematopoietic stem cells Area of Impact patients with metastatic breast cancer, especially HER2-low breast cancer Mechanism of Action EGFR-CAR_sIL15…

Specific Targeting Hypoxia Metastatic Breast Tumor with Allogeneic Off-the-Shelf Anti-EGFR CAR NK Cells Expressing an ODD domain of HIF-1α

Post author:
Post published:December 1, 2025
Post category:

Translational Candidate EGFR-CAR_sIL15 NK cells derived from CD34(+) umbilical cord blood hematopoietic stem cells Area of Impact patients with metastatic breast cancer, especially HER2-low breast cancer Mechanism of Action EGFR-CAR_sIL15…

HSC-Engineered Off-The-Shelf CAR-iNKT Cell Therapy for Multiple Myeloma

Post author:
Post published:December 1, 2025
Post category:

Translational Candidate stem cell-based off-the-shelf CAR-iNKT cells Area of Impact multiple myeloma (MM) Mechanism of Action The proposed therapeutic candidate can directly kill MM tumor cells. Unmet Medical Need MM…

Neural Stem cell-mediated oncolytic immunotherapy for ovarian cancer

Post author:
Post published:December 1, 2025
Post category:

Translational Candidate A clinically tested tumor-tropic neural stem cell (NSC) platform for effective distribution of oncolytic virotherapy to ovarian cancer metastases Area of Impact This NSC-delivered virotherapy approach will lead…

TRX103 for prevention of GvHD in patients receiving HLA mismatched HSCT for the treatment of hematologic malignancies

Post author:
Post published:December 1, 2025
Post category:

A Phase 1 Study of FT819 in Participants with Moderate to Severe Active Systemic Lupus Erythematosus

Post author:
Post published:December 1, 2025
Post category:

Therapeutic Candidate or Device iPSC-derived CD19 CAR T cell therapy Indication Systemic Lupus Erythematosus Therapeutic Mechanism Depletion of CD19+ B cells and plasmablasts Unmet Medical Need Potential for drug-free remission…

Subscribe to Receive CIRM News